MedTrace Logo

Clinical Study on the Effect of PTH on CYP3A4 Activity

NCT03695107 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-09-19

No results posted yet for this study

Summary

Parathyroid hormone (PTH) may play an important role in the down-regulation of CYP3A4 expression induced by Chronic kidney diseases (CKD). In the study of molecular mechanism, the research group found that the expression of CYP3A2 metabolic enzyme in rat liver decreased in the state of CKD.And PTH may down-regulate the expression of CYP3A4 metabolic enzyme by inhibiting the expression of Nuclear factor- Kilobuse (NF-kB) p65 subunit

Conditions

  • Chronic Kidney Diseases

Interventions

DRUG

Nifedipine controlled released tablets

lower blood pressure

Sponsors & Collaborators

  • The Third Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Yang GuoPing, doctor · The Third Xiangya Hospital of Central South University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-02
Primary Completion
2020-09-10
Completion
2020-09-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03695107 on ClinicalTrials.gov